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Abstract
Background: The inability of seasonal influenza vaccines to effectively protect against infection with antigenically drifted
viruses or newly emerging pandemic viruses underlines the need for development of cross-reactive influenza vaccines that
induce immunity against a variety of virus subtypes. Therefore, potential cross-protective vaccines, e.g., whole inactivated
virus (WIV) vaccine, that can target conserved internal antigens such as the nucleoprotein (NP) and/or matrix protein (M1)
need to be explored.
Methodology/Principal Findings: In the current study we show that a WIV vaccine, through induction of cross-protective
cytotoxic T lymphocytes (CTLs), protects mice from heterosubtypic infection. This protection was abrogated after depletion
of CD8+ cells in vaccinated mice, indicating that CTLs were the primary mediators of protection. Previously, we have shown
that different procedures used for virus inactivation influence optimal activation of CTLs by WIV, most likely by affecting the
membrane fusion properties of the virus. Specifically, inactivation with formalin (FA) severely compromises fusion activity of
the virus, while inactivation with b-propiolactone (BPL) preserves fusion activity. Here, we demonstrate that vaccination of
mice with BPL-inactivated H5N1 WIV vaccine induces solid protection from lethal heterosubtypic H1N1 challenge. By
contrast, vaccination with FA-inactivated WIV, while preventing death after lethal challenge, failed to protect against
development of disease and severe body weight loss. Vaccination with BPL-inactivated WIV, compared to FA-inactivated
WIV, induced higher levels of specific CD8+ T cells in blood, spleen and lungs, and a higher production of granzyme B in the
lungs upon H1N1 virus challenge.
Conclusion/Significance: The results underline the potential use of WIV as a cross-protective influenza vaccine candidate.
However, careful choice of the virus inactivation procedure is important to retain membrane fusion activity and full
immunogenicity of the vaccine.
Citation: Budimir N, Huckriede A, Meijerhof T, Boon L, Gostick E, et al. (2012) Induction of Heterosubtypic Cross-Protection against Influenza by a Whole
Inactivated Virus Vaccine: The Role of Viral Membrane Fusion Activity. PLoS ONE 7(1): e30898. doi:10.1371/journal.pone.0030898
Editor: Man-Seong Park, Hallym University, Republic of Korea
Received August 24, 2011; Accepted December 23, 2011; Published January 27, 2012
Copyright:  2012 Budimir et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was partially performed in the context of project T214-4-1 financed by Top Institute Pharma, The Netherlands and by Jan Kornelis de Cock
Stichting. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: Dr. Louis Boon is CSO at Bioceros BV. This does not alter the authors’ adherence to all the PloS One policies on sharing data and materials.
* E-mail: aalzen.de.haan@umcg.nl
Introduction
Influenza represents one of the major health burdens worldwide
[1]. Although vaccination is the cornerstone of protection against
influenza, currently used seasonal vaccines elicit a narrow strain-
specific antibody response that neutralizes antigenically matched
virus strains, but fails to protect against antigenically drifted strains
or newly emerging pandemics viruses [2,3]. Protection against
different influenza virus subtypes and variants requires the
development of vaccines that are capable of inducing hetero-
subtypic immunity [4]. Such vaccines should target not only the
variable surface antigen of the virus, hemagglutinin (HA), but also
more conserved internal antigens, such as the nucleoprotein (NP)
and/or matrix protein (M1) [5,6].
One strategy to induce heterosubtypic immunity is vaccination
with a formulation that has the capacity to induce cross-reactive
CD8+ cytotoxic T lymphocyte (CTL) responses against conserved
antigens shared by different influenza virus subtypes [5,7,8]. CTL-
mediated heterosubtypic immunity, although unable to neutralize
the virus and prevent infection, could facilitate clearance of the
virus, thereby controlling the course of infection [5,9].
Previously, we reported that vaccination of mice with whole
inactivated virus (WIV) induces activation of naive and primed
CTLs specific for NP [10]. Importantly, the activation of such
CTLs, especially the priming of naive cells, was influenced by the
way in which the virus was inactivated. This was most likely due to
differential effects of the inactivation procedure on viral mem-
brane fusion properties. It has been suggested that inactivation of
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Syncytial Virus, using formalin (FA) or b-propiolactone (BPL) can
induce distortion of antibody epitopes or suppress antigen
processing [11,12]. Interestingly, we showed that inactivation of
influenza virus using FA severely compromises the membrane
fusion activity of WIV. In contrast, inactivation using BPL largely
preserves viral membrane fusion activity. Moreover, vaccination
with FA-inactivated WIV (FA-WIV) primes naive CD8+ T cells
less effectively than vaccination with BPL-inactivated WIV (BPL-
WIV). After receptor-mediated endocytosis of WIV particles by
antigen-presenting cells (APC), membrane fusion activity most
likely facilitates the ‘‘escape’’ of viral antigens from endosomes into
the cytosol. Here influenza antigens can be processed and cross-
presented to CD8+ T cells in an MHC class I-restricted manner
[13,14,15].
In the current study, we investigate whether immunization of
mice with WIV (H5N1) protects against lethal heterologous
challenge (H1N1). We specifically investigated the extent to which
such protection might depend on the inactivation procedure used
in the production of WIV and, consequently, membrane fusion
activity. The cross-protective capacity of WIV was compared
directly with standard inactivated influenza vaccines, both subunit
and split.
Mice vaccinated with BPL-WIV were protected against lethal
heterologous challenge and the development of disease symptoms.
This cross-protection was mediated by CD8+ cytotoxic T cells. By
contrast, vaccination with FA-WIV, although protecting from
virus-induced death, failed to prevent severe body weight loss
associated with decrease in daily activity. Mice vaccinated with
subunit or split vaccine did not survive lethal challenge with
heterologous virus. These data demonstrate that vaccination with
WIV, but not subunit or split vaccine, induces cross-protection
against lethal heterologous infection. Importantly, our findings
highlight the impact of virus inactivation protocols on the overall
immunogenicity of the vaccine formulation and indicate that the
preservation of membrane fusion activity is critical for optimal
efficacy.
Results
Heterosubtypic cross-protection induced by vaccination
with WIV
To investigate the capacity of influenza WIV vaccine to induce
cross-protective immunity, we vaccinated mice with WIV derived
from NIBRG-14 virus, a reassortant containing the surface
antigens of A/Vietnam/1194/2004 (H5N1) virus and the internal
core of A/PR/8/34 (H1N1) virus, and subsequently challenged
the animals with PR/8 virus. The extent to which cross-protection
depends on the mode of virus inactivation was assessed by
comparing FA-WIV with BPL-WIV. FA-WIV was produced by
incubation of NIBRG-14 influenza virus with 0.01% FA for 7 days
at 4uC [16]. BPL-WIV was produced by incubation of NIBRG-14
virus with 0.1% BPL for 24 hr at 4uC. After either inactivation
protocol, viral replicative capacity was completely destroyed (Fig.
S1).
C57Bl/6 mice were immunized twice with FA-WIV or BPL-
WIV subcutaneously (s.c.) at a dose equivalent to 6 mg of viral HA.
Two other groups of mice were vaccinated with subunit or split
vaccine, and a control group was mock-vaccinated with vehicle
buffer. After the second immunization, animals were exposed to a
lethal total respiratory tract challenge with 100 PFU (correspond-
ing to 2610
2 TCID50) of live PR/8 virus. All mice were monitored
for body weight change, and euthanized when their body weight
loss exceeded 20%.
Over the course of 14 days post-challenge, only mice vaccinated
with BPL-WIV survived lethal heterosubtypic challenge without
body weight loss or apparent symptoms of disease (Fig. 1a and 1b).
By contrast, in the group of mice vaccinated with FA-WIV, 5 out
of 12 animals developed severe disease symptoms combined with
more than 15% body weight loss. By the end of the follow-up
period, these mice slowly recovered and regained their normal
body weight. This difference in the quality of protection induced
by vaccination with BPL-WIV or FA-WIV was statistically
significant by Fisher’s exact test (Fig. 1a). Mice vaccinated with
subunit or split vaccine were not protected from heterosubtypic
challenge. Similar to mock-vaccinated mice, these animals lost
more than 20% of their body weight within 7 days post-challenge,
and all of them were euthanized on the basis of pre-established
criteria by day 8 (Fig. 1a and 1b).
Next, we assessed the capacity of BPL-WIV or FA-WIV to
induce clearance of influenza virus from the lungs of challenged
mice. Although both vaccines led to improved virus clearance, the
dynamics of clearance were significantly different for the two
vaccination groups. On day 4 post-challenge, mice immunized
with BPL-WIV had lower virus titers in the lungs compared to
mice immunized with FA-WIV. By day 6, mice in both
vaccination groups had lower virus titers compared to those
measured on day 4. Again, the titers in mice vaccinated with BPL-
WIV were significantly lower compared to the titers in mice
vaccinated with FA-WIV. Virus titers in the lungs of mock-
vaccinated mice and mice vaccinated with either split or subunit
vaccines remained high on both days (Fig. 2).
Role of antibodies in cross-protection induced by
vaccination with WIV
The results presented above show that vaccination of mice with
BPL-WIV derived from H5N1 virus induced better protection
from disease symptoms and more rapid clearance of hetero-
subtypic H1N1 virus than vaccination with FA-WIV, split or
subunit vaccine derived from the same H5N1 virus. To rule out
the possibility that this difference was due to the more efficient
induction of antibodies against HA by BPL-WIV, we determined
the hemagglutination-inhibition (HI) titers against the vaccine
(H5N1) and challenge (H1N1) viruses induced by these vaccine
formulations. Pre-challenge sera of immunized mice were
collected and tested for the level of HI antibodies. BPL-WIV
and FA-WIV induced similar levels of HI antibodies against the
vaccine (H5N1) strain, which were significantly higher compared
to titers induced by split and subunit vaccine. In contrast, neither
of the vaccines induced detectable levels of HI antibodies cross-
reactive with the challenge (H1N1) strain (Fig. 3). This finding
implies that antibodies detectable by HI assay most likely did not
contribute significantly to the observed cross-protection (Fig. 3).
Cross-protection observed after vaccination with BPL-WIV
could be due to the activity of neutralizing antibodies that are
incapable of inhibiting hemagglutination but are capable of
binding to, for example, the stem region and/or fusion peptide of
HA, thus preventing HA-mediated membrane fusion and
infection. We therefore performed PR/8 microneutralization
assay to screen for the existence of possible cross-neutralizing
antibodies in pre-challenge sera of mice vaccinated with H5N1
BPL-WIV. Figure 4 shows that sera from mice immunized with
H5N1 BPL-WIV have only a minimal capacity to neutralize PR/8
virus when compared to sera from mice immunized with PR/8-
derived vaccine and challenged with PR/8 virus. This suggests
that cross-reactive antibodies do not play a major role in the
observed protection induced by vaccination with BPL-WIV.
Cross-Protective Influenza Vaccine
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vaccination with WIV
To investigate whether the observed cross-protection induced
by immunization with BPL-WIV was mediated by CD8+ CTLs,
we depleted CD8+ cells from mice immunized with BPL-WIV by
intraperitoneal (i.p) administration of CD8+ cell depletion
antibody on three consecutive days immediately prior to
challenge, with two additional doses administered post-challenge.
In peripheral blood (Fig. S2) and spleen (data not shown), .98%
of CD8+ cells were depleted. Comparable to mock-vaccinated
mice, BPL-WIV-vaccinated mice were not protected against lethal
heterosubtypic challenge after depletion of CD8+ T cells (Fig. 5a).
By day 9 post-challenge, most of these mice exhibited more than
20% body weight loss and had to be euthanized. Virus titers
measured in the lungs of these animals were high and did not differ
from the titers observed in the lungs of mock-vaccinated mice
(Fig. 5b). These data indicate that the cross-protection induced by
vaccination with WIV is mediated primarily by CD8+ CTLs.
Induction of CTL responses by BPL-WIV and FA-WIV: the
role of membrane fusion activity
Previously, we showed that FA-treatment abolishes the
membrane fusion activity of WIV and that such a formulation
has a decreased capacity to prime CTL activity in mice [10]. Here,
we first confirmed that the FA-WIV used in the present study
completely lacked membrane fusion activity as assessed on the
basis of hemolysis activity (Fig. 6). By contrast, up to 80% of the
membrane fusion activity was preserved in the BPL-WIV
preparation (Fig. 6). Importantly, the difference in hemolysis
induced by BPL-WIV or FA-WIV was not due to a difference in
erythrocyte binding, as determined by hemagglutination assay
(data not shown).
Next, we compared the levels of influenza-specific CTLs
induced by FA-WIV and BPL-WIV in peripheral blood and
spleen. In PBMCs from immunized mice, pre-challenge, CTLs
specific for influenza NP366–374 were detected with cognate MHC
class I tetramers in both groups of mice (Fig. 7a). However, the
Figure 1. Body weight change and survival of vaccinated mice after heterologous challenge. Mice were vaccinated twice with vaccines
derived from H5N1 virus (BPL-WIV, FA-WIV, split, subunit) or mock-vaccinated with HNE, and then challenged with H1N1 virus. (A) After challenge,
animals were monitored daily for body weight change. Body weight loss of more than 15% (solid line) associated with decline in daily activity was
considered to represent severe symptoms. Body weight loss of more than 20% was an indication for euthanasia (dashed line). Each group contained
12 animals, 6 of which were followed up for 6 days and then sacrificed for the measurement of immune response parameters; the other 6 mice were
monitored for 14 days. A higher proportion of animals vaccinated with FA-WIV exhibited significant body weight loss and severe disease symptoms
compared to animals vaccinated with BPL-WIV (p,0.05; Fisher’s exact test). (B) All mice vaccinated with either FA-WIV or BPL-WIV survived the
heterologous challenge based on a body weight loss of less than 20%, as indicated above. In contrast, mock-vaccinated mice or mice that received
either the split or subunit vaccines did not survive the challenge.
doi:10.1371/journal.pone.0030898.g001
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vaccinated with fusion-active BPL-WIV compared to mice
vaccinated with fusion-inactive FA-WIV. Notably, an early
accumulation of NP-specific CTLs in the spleen was observed 4
days post-challenge in mice vaccinated with fusion-active BPL-
WIV, but not in mice receiving fusion-inactive FA-WIV (Fig. 7b).
By day 6 post-challenge, this population decreased slightly.
Influx of specific CTLs into the lungs of WIV-vaccinated
mice after infection
Finally, we investigated whether the superior protection induced
by fusion-active BPL-WIV, compared to fusion-inactive FA-WIV,
was associated with a higher influx of cytotoxic CD8+ T cells into
the lungs as the site of infection. Lung-associated lymphocytes
were isolated from mice euthanized on day 4 or 6 post-challenge
and influenza NP366–374-specific CTLs were enumerated by
tetramer staining. Additionally, bronchoalveolar lavages (BALs)
were collected to measure the level of locally produced granzyme
B as an indicator of cytotoxic effector activity. On day 4 and 6
post-challenge, higher levels of NP-specific CTLs were detected in
the lungs of mice vaccinated with fusion-active BPL-WIV
compared to mice vaccinated with fusion-inactive FA-WIV
(Fig. 8a). At the same time, local granzyme B levels were
significantly higher in mice vaccinated with fusion-active BPL-
WIV compared to the levels observed in mice vaccinated with
fusion-inactive FA-WIV (Fig. 8b). Thus, the influx of NP-specific
CTLs in the lungs and local production of granzyme B correlated
with early clearance of influenza virus from the lungs of mice
vaccinated with fusion-active BPL-WIV.
Discussion
In this study, we show that vaccination of mice with a whole
inactivated influenza virus vaccine induces cross-protection against
heterosubtypic challenge, in contrast to vaccination with either
subunit or split vaccines. Importantly, we demonstrate that the
procedure used for virus inactivation in the production of WIV
Figure 2. Virus titers in the lungs of vaccinated mice after
heterologous challenge. Virus titers in the lungs of mice vaccinated
with the indicated formulations were measured at days 4 and 6 after
challenge. Bars represent mean titer6SEM of three mice. Mice
vaccinated with either BPL-WIV or FA-WIV had lower virus titers in
the lungs at both days 4 and 6 compared to the titers in mice
vaccinated with split vaccine, subunit vaccine or HNE buffer (p,0.05 for
all comparisons; Mann-Whitney U test). Furthermore, in mice vaccinated
with WIV, virus titers were lower at day 6 compared to titers at day 4
post-challenge (p,0.05; Mann-Whitney U test). Finally, significantly
lower titers were observed in mice vaccinated with BPL-WIV compared
to titers in mice vaccinated with FA-WIV, both at day 4 and day 6
(p,0.05; Mann-Whitney U test). No virus was detected in surviving mice
at day 14 after challenge (n.d., not detectable).
doi:10.1371/journal.pone.0030898.g002
Figure 3. H5N1- and H1N1-specific HI antibodies measured in
pre-challenge sera of vaccinated mice. Bars indicate the geometric
mean titers6SEM of 9 mice per vaccination group. HI antibodies
specific for H5N1 were detected in all vaccination groups (BPL-WIV, FA-
WIV, subunit and split), with significantly higher titers measured in mice
vaccinated with BPL- and FA-WIV. In contrast, HI antibodies against PR/8
(H1N1) were not observed in any of the mice (n.d., not detectable).
doi:10.1371/journal.pone.0030898.g003
Figure 4. H1N1-neutralization antibodies measured in pre-
challenge sera of mice vaccinated with H5N1 BPL-WIV. Bars
indicate the geometric mean titers6SEM of 6 mice in the H5N1 BPL-WIV
vaccination group or the titer measured in the pooled sera from 10
mice vaccinated with H1N1 PR/8-derived vaccine and challenged with
PR/8 virus. Sera from mice vaccinated with H5N1 BPL-WIV showed very
low neutralization activity against H1N1 PR/8.
doi:10.1371/journal.pone.0030898.g004
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quently the extent of cross-protection. Subunit and split vaccines
proved unable to induce influenza-specific CTL activity. In
contrast, vaccination with BPL-WIV induced a strong CTL
response associated with rapid clearance of virus from the lungs of
challenged mice and an apparent absence of disease symptoms. In
comparison, vaccination with FA-WIV induced lower levels of
CTLs associated with a slower rate of virus clearance and the
development of disease symptoms that gradually regressed by the
end of the follow-up period. These differences in the magnitude of
the CTL response and the efficacy of cross-protection observed
after vaccination with the different WIV preparations were linked
to the effects of the inactivation procedures on viral membrane
fusion activity.
The observed cross-protection induced by vaccination with
WIV appears to be mediated primarily by influenza-specific CTL
activity. Indeed, depletion of CD8+ cells in vaccinated mice
abrogated cross-protection against heterosubtypic challenge. This
rules out the possibility that anti-HA antibodies play a major role.
Accordingly, cross-reactive HI antibodies specific for the challenge
(H1N1) virus were undetectable in the H5N1-vaccinated mice.
Recent reports have shown that antibodies against the conserved
stem region of HA or against neuraminidase (NA) display cross-
reactivity among different influenza subtypes [17,18,19], and these
antibodies would not be detected in standard HI assays.
Microneutralization assays could, however, identify these antibod-
ies. In our hands sera of mice immunized with H5N1 WIV showed
minimal A/PR/8/34 virus-neutralizing capacity in vitro. Although
low levels of cross-reactive antibodies and, possibly cross-protective
CD4+ T cells [20], may thus be elicited by vaccination with WIV,
these effector mechanisms apparently are not strong enough in
isolation to substantially suppress viral replication, as shown in
vaccinated mice with depleted CD8+ cells. Thus, specific CTLs
appear to mediate the observed cross-protection of WIV-
vaccinated mice against heterosubtypic challenge.
The difference in cross-protection induced by WIV on one
hand, and by subunit and split vaccines on the other, is correlated
to the (in)ability of these vaccines to prime specific CTL activity. A
major requirement for the induction of influenza-specific CTLs is
the presence of conserved viral antigens in the vaccine, as CTL
responses are mainly directed against internal conserved proteins
[21,22,23]. Additional characteristics that may contribute to the
induction of CTL activity by WIV include the particulate structure
of the vaccine, which enables efficient uptake of vaccine antigens
by dendritic cells (DCs) through the process of receptor-mediated
endocytosis [24]. Finally, WIV contains viral genomic ssRNA,
which acts as an intrinsic adjuvant, activating TLR7-signaling in
DCs [25]. This ssRNA-induced TLR7-signaling has been shown
to contribute to superior activation of the humoral immune
Figure 5. Survival and reduction in lung virus titers after heterologous challenge depends on the presence of CD8+ cells. Mice were
vaccinated with H5N1-derived BPL-WIV or mock-vaccinated with HNE. Before heterologous lethal challenge, half of the animals (n=6) from each
vaccination group were randomly selected and received CD8+ cell depletion antibody treatment, as described in the Materials and Methods. (A) All
mice vaccinated with BPL-WIV survived the heterologous challenge, based on a body weight loss of less than 20%. In contrast, protection was lost in
CD8+ cell-depleted mice and survival rates were comparable to those of non-immune mice. (B) At the time of sacrifice, high levels of virus were
detected in the lungs of vaccinated CD8+ cell-depleted mice, similar to those observed in non-immune mice. At the same time point post-challenge,
virus could not be detected in the lungs of mice vaccinated with BPL-WIV in the absence of CD8+ cell depletion (n.d., not detectable).
doi:10.1371/journal.pone.0030898.g005
Figure 6. Effect of virus inactivation treatments on the
membrane fusion activity of WIV formulations. Guinea pig
erythrocytes were incubated with BPL-WIV or FA-WIV at different pH
values for measurement of pH-dependent viral membrane fusion. The
amount of released hemoglobin was measured by spectrophotometry
at 540 nm. Release of hemoglobin expressed relative to maximal
release of hemoglobin in water was used as a measure of fusion. Only
BPL-WIV showed the capacity to fuse to erythrocyte membranes when
incubated at low pH (4.6–5.6), as shown by the amount of released
hemoglobin. In contrast, in the same pH range, no fusion of FA-WIV
with erythrocyte membranes was detected.
doi:10.1371/journal.pone.0030898.g006
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indicating that priming of CTL activity by WIV critically depends
on TLR7-signaling (Budimir et al., manuscript in preparation).
The inability to induce cross-protective CTL activity is not
surprising for the subunit vaccine. Indeed, being composed of
isolated viral surface antigens, the subunit vaccine does not contain
internal CTL antigens. On the other hand, the split vaccine does
contain all the protein components of the influenza virus, yet in
our studies it failed to induce cross-protective CTL activity. Being
composed of non-particulate antigen, split vaccine may not be
taken up and processed efficiently by DCs [27]. Wagner et al.
showed that the induction of cross-priming required insertion of
split vaccine antigens into microspheres, facilitating targeting of
the antigens to the endosomes of DCs [26]. Also, the split vaccine
lacks intact immunostimulatory viral ssRNA [26], which, as
indicated above, contributes to the ability of WIV to prime CTLs.
It has been shown that coupling of split influenza vaccine antigen
to an alternative immunostimulatory TLR-ligand, CpG, boosts the
priming of CTL activity [28]. Thus, it appears that the specific
intrinsic properties of the vaccine formulation, such as composition
and structure, determine its capacity to induce cross-protective
CTL responses.
WIV as a non-replicating vaccine presumably activates target
CTLs through cross-priming, mediated by professional APCs,
particularly DCs [29–32]. After being taken up by DCs, vaccine
antigens end up in the endosomal compartment. From there, these
antigens have to ‘‘escape’’ to the cytosol where they can enter the
MHC class I antigen presentation pathway. Indeed, Bender et al.
have demonstrated that the delivery of WIV-derived antigen to the
cytosol of APCs is essential for successful priming of CTLs [33].
Figure 7. BPL-WIV induces higher levels of NP-specific CD8+ T cells compared to FA-WIV. (A) Numbers of influenza NP366–374-specific
CD8+ T cells were determined before challenge in the peripheral blood of mock-vaccinated mice and mice vaccinated with either BPL-WIV or FA-WIV.
Bars indicate the mean percentage6SEM of 9 mice per group. Vaccination of mice with BPL-WIV induced significantly higher levels of NP366–374-
specific CD8+ T cells compared to levels induced by FA-WIV (p,0.05; Mann-Whitney U test). (B) Four days after challenge, the mean percentage of
influenza NP366–374-specific CD8+ T-cells in the spleen was significantly higher in mice vaccinated with BPL-WIV compared to mice vaccinated with
FA-WIV (p,0.05; Mann-Whitney U test, n=3).
doi:10.1371/journal.pone.0030898.g007
Figure 8. BPL-WIV vaccination results in a higher post-challenge influx of cytotoxic CD8+ T cells into the lungs. (A) The accumulation
of NP366–374-specific CD8+ T cells in the lungs of mice vaccinated with BPL-WIV or FA-WIV was measured on days 4 and 6 post-challenge. Bars indicate
the mean percentage6SEM of 3 mice per group. On days 4 and 6 post-challenge, significantly higher percentages of NP366–374-specific CD8+ T cells
were observed in mice vaccinated with BPL-WIV compared to mice vaccinated with FA-WIV (p,0.05; Mann-Whitney U test). (B) The higher influx of
NP366–374-specific CD8+ T cells in BPL-WIV vaccinated mice was accompanied by a higher local production of granzyme B compared to levels
measured in mice vaccinated with FA-WIV (p,0.05; Mann-Whitney U test). In both the BPL-WIV and FA-WIV vaccinated groups, levels of granzyme-B
were significantly enhanced on day 6 compared to levels measured on day 4 (p,0.05; Mann-Whitney U test).
doi:10.1371/journal.pone.0030898.g008
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‘‘escape’’ of internal viral antigen from the endosome to the APC
cytosol, where it can be processed and presented to CD8+
cytotoxic T cells through the MHC class I pathway. Previously, we
observed that inactivation of membrane fusion activity of WIV
diminishes its capacity to prime specific CTL activity [10]. Here,
we show that fusion-active WIV induces superior heterosubtypic
cross-protection in mice compared to fusion-inactive WIV. This
indicates that activation of CTLs through cross-presentation of
WIV-derived antigens depends on the fusogenic properties of the
vaccine.
Some procedures used for virus inactivation can severely impair
the membrane fusion properties of the virus, thereby affecting the
capacity of the vaccine to induce CTL activity. In this study, we
have shown that an inactivation protocol, relying on treatment of
influenza virus with formaldehyde (FA), completely abolishes
membrane fusion activity of the virus. This protocol is commonly
used by vaccine manufacturers to generate WIV [16]. In contrast,
virus inactivation based on treatment with b-propiolactone (BPL)
largely preserves membrane fusion activity. In our studies, only
vaccination with BPL-WIV prevented severe body weight loss and
the development of disease symptoms by inducing optimal CTL
activity in the lungs and rapid clearance of the virus (Ref [10];
Fig 1a, 2, 7a). By contrast, vaccination with FA-WIV gave only
partial protection, with 5 of 12 vaccinated mice showing severe
body weight loss and disease symptoms. This suboptimal cross-
protection was associated with a comparatively low CTL response.
Our findings therefore imply that preservation of virus membrane
fusion activity should be taken into account when WIV vaccines
are generated.
The important role of CTLs specific for conserved influenza
antigens, such as NP, in protection against influenza infection in
humans and mice has been recognized and reported earlier [5,34].
In the present study, we show that vaccination with WIV induces
high levels of specific CTLs in blood and spleen. After
heterologous challenge, these CTLs infiltrate the lungs, where
they are already detectable by day 4 post-infection. These findings
are in line with those of Fonteneau et al., who showed that WIV
can induce in vitro proliferation of influenza-specific CD8+ T cells
in humans [29]. Critically, we also show that CTLs induced by
vaccination with WIV protect mice from lethal heterosubtypic
challenge. In a recent study, Furuya et al. showed that
immunization of mice with WIV produced using a different
inactivation method (c-irradiation) also protects mice against lethal
infection with heterologous virus [35]. By contrast, Bodewes et al.
reported that immunization with WIV induced poor activation of
CTLs and a low level of cross-protection [36]. The discrepancy
between our results and those of Bodewes et al. could be explained
on two levels. First, Bodewes et al. used an FA-based protocol for
inactivation of the virus, which interferes with optimal priming of
CTL activity, as discussed above. Second, the difference in the
route of administration used by us and Bodewes et al. could be an
explanation for the different observations. In our experiments, the
vaccine was administered through the s.c. route, while Bodewes et
al. used i.m. injection. Several studies have demonstrated that the
route of antigen administration can affect the magnitude of CTL
activation as well as the diversity of the induced CTL response
[37,38]. For example, Combadiere et al. showed that transcuta-
neous application of influenza vaccine to humans induced better
CD8+ T cell responses, in terms of both magnitude and quality,
than injection though the i.m. route [37].
The inability of seasonal influenza vaccines to protect against
drifted or newly emerging, potentially pandemic, viruses under-
lines the need for broadly cross-protective influenza vaccines.
Clearly, induction of immunity against conserved viral antigens is
crucial for-cross protection [6,39,40]. In this respect, there are
specific lessons to be learned from the recent swine-origin H1N1
pandemic. Unexpectedly, the virus induced relatively mild disease
[41]. Although cross-reactive antibodies may have contributed to
the protection against the pandemic virus [18,39], recent studies
have suggested that the development of severe disease and
mortality were largely prevented by existing memory CD8+
cytotoxic T cells specific for highly conserved virus proteins, such
as NP and M1, induced by a prior infection with epidemic H1N1
virus [42]. In addition, other studies showed that human memory
CD8+ T cells cross-react to a high extent with conserved NP and
M1 epitopes from the highly pathogenic avian influenza H5N1
virus [43,44]. In the present study, we demonstrated the cross-
protective potential of properly inactivated influenza WIV, using a
combination of NIBRG-14 (H5N1) vaccine and A/PR/8/34
(H1N1) challenge virus, which share internal antigens, including
NP. Although this may favor an optimal response to challenge
with the heterosubtypic virus, published data point to the high
degree of internal antigen conservation, not only among different
human influenza virus strains or subtypes but also between human
and zoonotic viruses. In addition, it has been demonstrated that
CTLs against internal viral antigens display a certain level of cross-
reactivity to non-identical antigens [42–44]. Although not capable
of preventing the viral infection itself, such CTL-mediated
immunity can control the course of the disease by keeping the
viral load suppressed [5,6].
Although a renewed interest for WIV as a candidate cross-
protective influenza vaccine has emerged, concerns about its
reactogenicity remain. It is of interest to note, however, that this
reactogenicity is not a uniform finding for all previously tested
WIV vaccines and, additionally, also appears to relate to other
factors such as vaccine mass and HA content [45]. With respect to
the latter, the use of HA content for dosing of WIV vaccines gave a
better correlate for reactogenicity than did chicken-cell agglutina-
tion, an older test for standardizing antigenic content of influenza
vaccines [45]. Thus, improved analysis and standardization of
WIV vaccines could reduce its reactogenicity.
In summary, we show here that one of the oldest influenza
vaccines, WIV, induces heterosubtypic cross-protection that is
closely dependent on specific CTL activity. Importantly, the
capacity of WIV to induce an optimal CTL response, and
consequently cross-protection, is strongly influenced by the
procedure used for virus inactivation. WIV is therefore a
promising candidate cross-protective influenza vaccine provided
that suitable inactivation procedures, which retain viral fusion
activity, are employed.
Materials and Methods
Ethics statement
All mouse experiments were performed in strict accordance
with Dutch legislation on animal experiments (‘‘Wet op de
dierproeven’’, 1977; modified in 1996 with implementation of the
European guidelines 86/609/EEG and ‘‘Dierproevenbesluit
1985’’) and approved by the Ethics Committee on Animal
Research of the University Medical Center Groningen (Permit
number: 5101).
Virus strains and vaccines
H5N1 virus (NIBRG-14, a 6:2 reassortant strain of A/PR/8/34
and A/Vietnam/1194/2004) cultured on Madine-Darby Kidney
(MDCK) cells and egg-derived H1N1 virus (PR/8/34) were a kind
gift from Solvay Biologicals (Weesp, The Netherlands). NIBRG-14
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tions: WIV, split and subunit. WIV vaccine was prepared either by
24 hr inactivation of the virus with 0.1% BPL (Acros Organics,
Geel, Belgium) at room temperature, followed by dialysis for 24 hr
against HNE buffer (5 mM HEPES, 150 mM NaCl, 0.1 mM
EDTA, pH 7.4), or by incubation for 7 days in presence of 0.01%
FA, with constant, mild stirring, followed by dialysis for 24 hr
against HNE.
Inactivation of the vaccines was tested by performing serial
passages on eggs, according to the protocol published in the
European Pharmacopeia [46]. Specifically, one vaccine dose
(20 mg of total viral protein) was inoculated into the allantoic cavity
of each of 20 fertilized eggs and incubated at 33uC for 3 days. As a
replication-positive control, 1 hemagglutination unit (HAU) of live
NIBRG-14 virus was injected into the eggs. Portions of 1 ml of
allantoic fluid from all the eggs were pooled, and 200 ml was
inoculated into new eggs. This passage procedure was repeated
one more time. Finally, after the last passage, allantoic fluid was
harvested and tested for the presence of replicative virus by a
hemagglutination test, as described elsewhere [47].
Fusion activity of WIV preparations was assessed using a
hemolysis assay, as described previously [10].
BPL-WIV was processed to split vaccine according to a
published protocol [48]. Subunit vaccine was prepared by
processing BPL-WIV as described previously [49].
The protein content of all vaccine preparations was determined
using the Bio-Rad protein assay kit (Bio-Rad Laboratories,
Veenendaal, The Netherlands).
Vaccination and challenge
Female C57Bl/6 mice, aged 6–8 weeks, were purchased from
Harlan, The Netherlands. Every vaccination group contained 18
mice and was randomly divided into 3 subgroups that were
analyzed for viral titers and immune response parameters at days
4, 6 and 14 post-challenge, respectively. Mice were vaccinated
twice subcutaneously (s.c.) on days 0 and 21. Animals from all
vaccination groups received an equal amount of 266.7 mg HA per
vaccine dose, corresponding to 2620 mg of total protein in the case
of the split and WIV vaccines [50]. One week after the booster
immunization, mice were anesthetized and inoculated intranasally
with 100 PFU (corresponding to 2610
2 TCID50) of PR/8 (H1N1)
in 40 ml HNE. A dose of 100 PFU was used because this was the
minimal dose which reproducibly induced lethal infection in 100%
mice. Following challenge, mice were monitored daily for body
weight change. Body weight loss of more than 15% associated with
decline in daily activity was considered to represent severe
symptoms. Body weight loss of more than 20% was considered
an indication for euthanasia. On day 4 and 6 post-challenge, 6
mice from each vaccination group were euthanized and blood,
spleen, lungs and bronchoalveolar lavage (BAL) were collected.
Mice that did not undergo more than 20% body weight loss were
euthanized on day 14 post-challenge for analysis of virus titers and
different immunological parameters.
Vaccination, blood sampling, challenge and euthanasia were
performed under isoflurane anesthesia.
Depletion of CD8+ cells
Depletion of CD8+ cells was performed by administration of
purified CD8-specific depleting monoclonal antibody (clone
YTS169). On days 22, 23 and 24 after the start of the experiment,
mice were injected i.p. with 200 mg of the depletion antibody.
Further, starting from day 1 post-challenge, mice received a single
i.p. injection of the depletion antibody every 7 days. The efficacy
of CD8+ cell depletion throughout the experiment was determined
by staining of PBMCs with anti-mouse CD8a antibody (Im-
munosource, Zoersel, Belgium) and flow cytometry analysis. Blood
samples were taken, and PBMCs isolated each time before
injection of the depletion antibody dose.
Lung virus titer measurements
On days 4, 6 and 14 post-challenge, the lungs of mice were
dissected and collected in 1 ml phosphate buffered saline (PBS) on
ice, homogenized mechanically and centrifuged for 10 min at
3506g. Supernatants were collected, snap-frozen and stored at
280uC until further processing.
For viral titrations, MDCK cells were seeded in flat-bottom 96-
wells plates and incubated in serum-free Episerf medium
(Invitrogen, Leek, The Netherlands) for 2 days in a CO2 incubator
(37uC, 5% CO2). Two-fold dilutions of lung supernatants were
then prepared in duplicate and 100 ml of each dilution was added
to the MDCK cells, followed by a 1 h incubation at 37uC, 5%
CO2. After incubation, the culture medium was replaced by
medium supplemented with 6 mg/ml TPCK trypsine (Sigma-
Aldrich, Zwijndrecht, The Netherlands) per well, and cells were
incubated for additional 72 hr. On day 7, cell supernatants were
harvested and transferred to V-bottom 96-wells plates. The
presence of virus was detected using the hemagglutination assay
[47].
Tetramer staining of blood, spleen and lung lymphocytes
Pre-challenge blood samples were collected on the day of
challenge by performing orbital puncture under isoflurane
anesthesia. Samples were collected in tubes previously coated
with heparin and incubated for 5 min with ACK buffer (0.15 M
NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) to induce lysis of
erythrocytes. After 3 washes with FACS buffer (1% BSA, 5 mM
EDTA in PBS), cells were stained with anti-mouse CD8a-APC
antibody and influenza NP366–374-tetramer-PE. Soluble, biotiny-
lated AM9/H-2Db monomeric protein was produced and
tetramerized at a 4:1 molar ratio with PE-conjugated streptavidin
as described previously [51]. Dead cells were excluded using
7AAD viability solution (Immunosource). Flow cytometric analysis
was performed using a FACSCalibur flow cytometer (BD
Biosciences).
Spleens were dissected and collected on ice in Iscove’s Modified
Dulbeco’s Modified Eagle’s (IMDM) medium (Invitrogen) supple-
mented with 10% fetal bovine serum (FBS), 1% antibiotics and
0.1% b-mercaptoethanol. Splenocytes were isolated by homoge-
nizing spleens though cell strainers (BD Bioscinece, Breda, The
Netherlands) and resuspended in medium. After 10 min centrifu-
gation (3506g) at 4uC, erythrocytes were removed by lysis using
ACK buffer (0.15 M NH4Cl, 10 mM KHC03, 0.1 mM
Na2EDTA, pH 7.2). Finally, after an additional round of washing
in medium, cells were washed 3 times in FACS buffer and stained
according to the procedure described above.
Tetramer staining on lung derived lymphocytes was performed
as follows. Mice were anesthetized and lungs were perfused
through the heart with a total of 20 ml of PBS with heparin. After
perfusion, lungs were dissected and cut into small pieces using a
sterile scalpel, while cooled on ice. The pieces of lung tissue were
incubated at 37uC in presence of 1 mg/ml collagenase D (Roche,
Woerden, The Netherlands) for 3 hours. Next, lung homogenates
were forced through cell strainers (BD Biosciences) and washed 3
times with Dulbeco’s Modified Eagle’s medium (DMEM; PAA,
Colbe, Germany) supplemented with 2% FBS. Finally, lympho-
cytes were isolated using lympholyte density gradients (Sanbio,
Uden, The Netherlands) according to the manufacturer’s protocol.
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Granzyme B ELISA
Granzyme B production in the lungs of mice was measured in
BAL samples by ELISA (R&D Systems, Abingdon, United
Kingdom). Before testing, samples were centrifuged at 3506g
for 10 min and supernatants were harvested. Five different
dilutions were then prepared: a non-diluted sample, and 1:10,
1:50, 1:100 and 1:1000 diluted samples. The assay was performed
according to the manufacturer’s protocol.
Hemagglutination inhibition (HI) assay
Serial two-fold dilutions of NIBRG-14 and PR/8 virus stocks
were prepared in duplicates in V-bottom 96-wells plates. A
suspension of 1% guinea pig erythrocytes was added and gently
mixed with diluted virus. After incubation for 2 hr at room
temperature, 1 HAU was scored as the highest virus dilution at
which total hemagglutination was obtained. For determination of
the HI titer, pre-challenge sera of vaccinated mice were
complement-inactivated by incubating 75 ml aliquots for 30 min
at 56uC. Next, sera were mixed with 3 volumes (225 ml) of 25%
kaolin solution, incubated for 20 min at room temperature and
centrifuged for 2 min at 4006g. Supernatants were collected and
serially diluted two-fold in duplicate in V-bottom 96-wells plates.
The virus suspension containing 4 HAU (determined as described
above) and 1% guinea pig erythrocytes were then gently mixed
with the serum supernatants. Hemagglutination was allowed to
develop for 2 hr, and the highest dilution at which hemaggluti-
nation was inhibited was scored and used to calculate titers.
Microneutralization assay
MDCK cells were seeded in 96-wells flat-bottom plates and
cultured overnight in serum-free Episerf medium. The next day,
two-fold serial dilutions of sera, with starting dilution 1:10, were
prepared in 96-wells plates in quadruplicate. To each well, with
the exception of negative controls, 50 TCID50 of the challenge
PR/8 virus was added and plates were incubated for 2 hours at
37uC. Next, MDCK cells were washed once with Episerf medium,
and mixtures of serum and virus were added to the cells. Further
on, cells were incubated for 1 hr at 37uC. After the 1 hr
incubation, the culture supernatants were replaced by medium
supplemented with 6 mg/ml of TPCK trypsine and cells were
incubated for an additional 72 hr. On day 5, cell supernatants
were harvested and transferred to V-bottom 96-wells plates. The
presence of virus was detected using a hemagglutination assay
[47].
Statistical methods
Differences between vaccination groups with regard to the levels
of tetramer-positive cells, granzyme B production, HI and lung
virus titers were analyzed using the Mann-Whitney U test with a
confidence interval 95%. To enumerate the difference between
groups based on severe body weight loss, a Fisher’s exact test was
used. A value of p,0.05 was considered as statistically significant
and is indicated in the figures with an asterisk. Double and triple
asterisks indicate p values of ,0.01 and ,0.001, respectively.
Supporting Information
Figure S1 Assessment of viral inactivation status in the
FA-WIV and BPL-WIV vaccines. Influenza virus inactivation
was tested by performing serial passages on eggs. After the last
passage, allantoic fluids were tested for the presence of replicative
virus using the hemagglutination test. Virus titers measured in FA-
WIV and BPL-WIV samples were below the detection limit (n.d.,
not detectable). Results are presented mean6SEM (n=20 eggs).
(TIF)
Figure S2 Efficacy of CD8+ cell depletion in peripheral
blood of mice after injection of YTS169 antibody. On days
22, 23 and 24 after the start of experiment, mice were injected i.p.
with a single dose of the depletion antibody. Subsequently, starting
from day 1 post challenge, mice were injected with a single dose of
the depletion antibody every 7 days. To monitor the efficacy of
CD8+ cell depletion, blood samples were collected from mice on
day 24 and then immediately prior to each subsequent antibody
injection. As a control, blood was also sampled from mice that did
not receive the depletion antibody. Isolated PBMCs were surface
stained for CD8. To avoid multiple blood sampling from
individual animals, samples were taken only from two mice per
group at each time point. Representative flow cytometry plots are
shown demonstrating the efficacy of CD8 cell depletion. Data is
presented as the percentage of CD8+ cells within the total PBMC
population.
(TIF)
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